Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use

EQS Newswire / 24/11/2022 / 09:48 UTC+8 Kintor Pharma announced completion of phase I trial of the world’s first PROTAC compound (GT20029) for topical use     Suzhou, November 24, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the top-line results for its phase […]

Mazda: Mid-Term Management Plan Update and Management Policy up to 2030

HIROSHIMA, Japan, Nov 22, 2022 – (JCN Newswire via SEAPRWire.com) – Mazda Motor Corporation today announces an update to its Mid-Term Management Plan and basic management policies up to 2030. Taking into account the significant changes that have occurred in the business environment including countries’ environmental regulatory trends, heightened geopolitical risks, and rapid development of […]

Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US

EQS Newswire / 27/10/2022 / 17:58 UTC+8 Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US   Suzhou, October 27, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company […]

Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day

EQS Newswire / 08/09/2022 / 23:42 EST/EDT Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day Interim data from Phase 1/2 propionic acidemia (PA) multi-dose Paramount trial shows mRNA-3927 was well-tolerated to date, with encouraging early signs of potential for clinical benefit Interim data from Phase 1/2 glycogen storage disease 1a (GSD1a) single-dose […]

Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs

SYDNEY, AU, Sep 6, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates, enabling biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside […]

Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented

EQS Newswire / 30/08/2022 / 11:13 UTC+8 Kintor 2022 Interim Results: Pruxelutamide and KX-826 show positive results, business value has been presented   Suzhou, August 29, 2022 – Kintor Pharmaceutical Limited (“Kintor Pharma” or “the Company”, HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced its 2022 interim results […]

Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development, manufacturing and commercialization of therapies that address significant unmet medical needs, today announced its interim results for the six months ended 30 June […]

Nakamoto Games Entering New Growth Phase

Play-to-earn disruptor to finalize private sale token distribution ahead of schedule Mahe, Seychelles, June 25, 2022 – (SEAPRWire) -Nakamoto Games ($NAKA), the token powering the industry’s fastest-growing play-to-earn gaming ecosystem, is entering a new growth phase with exciting prospects. On Monday, June 27th, 2022, Nakamoto Games will release the last $NAKA token allocation batch to private sale investors. […]

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

HONG KONG, Jun 15, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject […]

Essex Bio-Technology Announces 2021 Financial Results

HONG KONG, Mar 22, 2022 – (ACN Newswire via SEAPRWire.com) – Essex Bio-Technology Ltd (“Essex” or the “Group”, Stock Code: 1061.HK) today announced the annual results for the year ended 31 December 2021. Highlights— The group’s turnover surged 67.4% to HK$1,637.7 million, Profit-After-Tax lifted 58% to HK$346.0 million; — Sales coverage increased to around 10,500 […]

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

HONG KONG, Feb 7, 2022 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 […]

Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022

ADELAIDE, AUS, Jan 18, 2022 – (ACN Newswire via SEAPRWire.com) – Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. Avance […]

Phase I Clinical Trial of AIM mRNA COVID-19 Vaccine (LVRNA009) Won the Praise of the Industry for High Safety and Well Tolerance

HANGZHOU, CHINA, Jan 12, 2022 – (ACN Newswire via SEAPRWire.com) – On January 8, AIM Vaccine held a meeting at Shulan (Hangzhou) Hospital to report on the analysis results of the phase I clinical trial data of its mRNA COVID-19 vaccine (LVRNA009). Safety data on the phase I clinical trial was released by Director Chen […]

POSTPONED: January 2022 Dentist board exam Practical Phase in Manila; new schedule

MANILA, Philippines – The Professional Regulation Commission (PRC) announced Wednesday the postponement of the January 2022 Dentist board exam practical phase in Manila or National Capital Region (NCR) due to COVID-19 restrictions. PRC released Resolution No. 1472 s. 2022 to reschedule the January 6-11, 2022 Practical Phase of the Board Licensure Examination for Dentists (BLED) […]

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

TOKYO, Dec 24, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early Alzheimer’s disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). FDA granted Breakthrough Therapy designation for lecanemab […]

SinoMab Announces the Completion of Enrollment in Phase III Clinical Trial in China for its Flagship Product, SM03

HONG KONG, Nov 30, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (“SinoMab”, or the “Company”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 30 November 2021, SM03 (Suciraslimab) Phase III […]

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension

TOKYO, Nov 11, 2021 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today results of new clinical, biomarker and safety assessments of brain amyloid reduction and five-year clinical status of people living with early Alzheimer’s disease (AD) from the lecanemab Phase 2b 201 and the open-label extension (OLE) studies. The […]

MC and Kinki Sharyo Sign Contract with Egyptian Government for Rolling Stock Deliveries for Phase 1 of Cairo Metro Line 4

TOKYO, Nov 9, 2021 – (JCN Newswire via SEAPRWire.com) – Mitsubishi Corporation (MC) and The Kinki Sharyo Co., Ltd. (Kinki Sharyo) are pleased to announce that we have signed a contract with National Authority for Tunnels (NAT) to deliver 184 cars of rolling stock for Phase 1 of Cairo Metro Line 4(New CP 412). The […]

SinoMab, Sinovent and Everest Medicines Announce Licensing Agreement for Global Development and Commercialization of A Next-Generation BTK Inhibitor in Renal Diseases

HONG KONG, Sep 17, 2021 – (ACN Newswire via SEAPRWire.com) – SinoMab BioScience Limited (HKEX 3681.HK, “SinoMab”) announced with Suzhou Sinovent Pharmaceuticals Co., Ltd. (“Sinovent”) today that they have entered into an exclusive licensing agreement with Everest Medicines (HKEX 1952.HK, “Everest”) to out-license the right to develop and commercialize SN1011 (referred as “XNW1011” by Sinovent), […]